Peringatan Keamanan

There are currently no data available regarding an overdose with sotrovimab, and LD50 information is not available. If an overdose occurs, provide symptomatic and supportive treatment as required.L34430

Sotrovimab

DB16355

biotech approved investigational

Deskripsi

Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus.L34440 Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting.L34425, L34430, L34440 However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.L41369

Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.L39625,L39620

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) This antibody has undergone modifications for a potentially extended half-life and enhanced lung bioavailability.[L27296] The half-life of sotrovimab is longer than Fc-unmodified IgG due to the LS modification, however, specific values are not available in the literature.[L34430]
Volume Distribusi Sotrovimab is an Fc-enhanced human immunoglobulin G (IgG), and therefore has the potential for placental transfer.[L34430]
Klirens (Clearance) -

Absorpsi

A non-compartmental analysis determined that the mean Cmax after a 1 hour IV infusion of sotrovimab was 137 µg/mL and the mean Day 29 concentration was 34 µg/mL.L34430

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

387 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Sotrovimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Sotrovimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Sotrovimab.
Estrone Estrone may increase the thrombogenic activities of Sotrovimab.
Estradiol Estradiol may increase the thrombogenic activities of Sotrovimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Sotrovimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Sotrovimab.
Mestranol Mestranol may increase the thrombogenic activities of Sotrovimab.
Estriol Estriol may increase the thrombogenic activities of Sotrovimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Sotrovimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Sotrovimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Sotrovimab.
Tibolone Tibolone may increase the thrombogenic activities of Sotrovimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Sotrovimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Sotrovimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Sotrovimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Sotrovimab.
Zeranol Zeranol may increase the thrombogenic activities of Sotrovimab.
Equol Equol may increase the thrombogenic activities of Sotrovimab.
Estetrol Estetrol may increase the thrombogenic activities of Sotrovimab.
Promestriene Promestriene may increase the thrombogenic activities of Sotrovimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Sotrovimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Sotrovimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Sotrovimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Sotrovimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Sotrovimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Sotrovimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Sotrovimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Sotrovimab.
Formononetin Formononetin may increase the thrombogenic activities of Sotrovimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sotrovimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sotrovimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Sotrovimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Sotrovimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Sotrovimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sotrovimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sotrovimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Sotrovimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sotrovimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Sotrovimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Sotrovimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Sotrovimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sotrovimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sotrovimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Sotrovimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sotrovimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sotrovimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Sotrovimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sotrovimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Sotrovimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Sotrovimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Sotrovimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sotrovimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sotrovimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Sotrovimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Sotrovimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Sotrovimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Sotrovimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Sotrovimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Sotrovimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Sotrovimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Sotrovimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Sotrovimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Sotrovimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Sotrovimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Sotrovimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Sotrovimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Sotrovimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Sotrovimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Sotrovimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Sotrovimab.
Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Sotrovimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Sotrovimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Sotrovimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Sotrovimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Sotrovimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Sotrovimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Sotrovimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Sotrovimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Sotrovimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Sotrovimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Sotrovimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Sotrovimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Sotrovimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Sotrovimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Sotrovimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Sotrovimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Sotrovimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sotrovimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Sotrovimab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Sotrovimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Sotrovimab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Sotrovimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Sotrovimab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Sotrovimab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Sotrovimab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Sotrovimab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sotrovimab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Sotrovimab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Sotrovimab.

Target Protein

Spike glycoprotein S

Referensi & Sumber

Artikel (PubMed)
  • PMID: 33907512
    Ning L, Abagna HB, Jiang Q, Liu S, Huang J: Development and application of therapeutic antibodies against COVID-19. Int J Biol Sci. 2021 Apr 10;17(6):1486-1496. doi: 10.7150/ijbs.59149. eCollection 2021.
  • PMID: 33319649
    Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D: Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-Dec;12(1):1854149. doi: 10.1080/19420862.2020.1854149.
  • PMID: 32877828
    Owji H, Negahdaripour M, Hajighahramani N: Immunotherapeutic approaches to curtail COVID-19. Int Immunopharmacol. 2020 Nov;88:106924. doi: 10.1016/j.intimp.2020.106924. Epub 2020 Aug 21.
Link

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Sotrovimab
    Injection, solution, concentrate • 62.5 mg/1mL • Intravenous • US
  • Sotrovimab for Injection
    Solution • 500 mg / 8 mL • Intravenous • Canada • Approved
  • Xevudy
    Injection, solution, concentrate • 500 mg/8ml • Intravenous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul